Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests
Myriad Genetics, Inc. (MYGN)
Last myriad genetics, inc. earnings: 2/6 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
myriad.com/news-center/investor-information
Company Research
Source: GlobeNewswire
SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will present new data at the 2026 ASCO-GU conference supporting its Precise MRDTM (Molecular Residual Disease) Test, Prolaris® Prostate Cancer Prognostic Test and MyRisk® Hereditary Cancer Tests. These data highlight Myriad’s expanding role across the cancer care continuum, including ultra-sensitive molecular residual disease detection, prognostic stratification, and inherited cancer risk assessment. “The data Myriad is presenting at ASCO-GU suggest our oncology products go further than standard approaches to deliver unique insights for patients with cancer,” said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics. “Our MRD test may reveal clinically consequential information that may not have been attainable on first-generation tests. We demonstrate with deep statistical rigor that Prolaris is highly prognostic and addit
Show less
Read more
Impact Snapshot
Event Time:
MYGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MYGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MYGN alerts
High impacting Myriad Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
MYGN
News
- Why Myriad Genetics (MYGN) Stock Is Trading Up Today [Yahoo! Finance]Yahoo! Finance
- Myriad Genetics (NASDAQ:MYGN) had its price target lowered by analysts at Wells Fargo & Company from $6.50 to $6.00. They now have an "equal weight" rating on the stock.MarketBeat
- Myriad Genetics (NASDAQ:MYGN) had its "neutral" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Myriad Genetics Inc (MYGN) Q4 2025 Earnings Call Highlights: Surpassing Revenue Expectations ... [Yahoo! Finance]Yahoo! Finance
- Myriad Genetics's (NASDAQ:MYGN) Q4 CY2025 Sales Top Estimates, Stock Jumps 22% [Yahoo! Finance]Yahoo! Finance
MYGN
Earnings
- 2/23/26 - Beat
MYGN
Sec Filings
- 2/24/26 - Form S-3
- 2/24/26 - Form 10-K
- 2/23/26 - Form 8-K
- MYGN's page on the SEC website